1-6 of 6
Ana Nunes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)

Jenny M.H. Chen, Ina Zhang, James J. Wu, Sally W. Wade, Ana Nunes, Weimin Peng, Julia T. Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal D. Shah
Journal: Blood
Blood (2023) 142 (Supplement 1): 5136.
https://doi.org/10.1182/blood-2023-177741
Published: 2023
Journal Articles

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma

Nora Liebers, Hervé Finel, Dominic Edelmann, Guido Kobbe, Ben-Niklas Bärmann, Yasmina Serroukh, Didier Blaise, Dietrich W. Beelen, Carlos Solano, Maija Itäla-remes, Annoek E.C. Broers, Goda Choi, Nicolaus Kroeger, Jenny Louise Byrne, Jean-Jacques Tudesq, Ana Nunes, Rubina Siddiqi, Elande Baro, Dan Zheng, Ioana Kloos, Peter Dreger, Anna Maria Sureda Balari, Bertram Glass, Sascha Dietrich
Journal: Blood
Blood (2023) 142 (Supplement 1): 3494.
https://doi.org/10.1182/blood-2023-174368
Published: 2023
Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics

Swetha Kambhampati, Nausheen Ahmed, Mehdi Hamadani, Soyoung Kim, Michael T. Hemmer, Natalie S. Grover, Mazyar Shadman, Amer Beitinjaneh, L. Elizabeth Budde, James Gerson, Caron A. Jacobson, Frederick L. Locke, Dwivedy S. Nasta, Michael L. Wang, Wen-Kai Weng, Jiali Yan, Ana Nunes, David Dalton, James J. Wu, Amina Abdeldaim, Zhen-Huan Hu, Marcelo Pasquini, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 107.
https://doi.org/10.1182/blood-2023-179269
Published: 2023
Journal Articles

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan O. Oluwole, Patrick M. Reagan, David B. Miklos, Frederick L. Locke, Andre Goy, Caron A. Jacobson, Javier L. Munoz, Edouard Forcade, Max S. Topp, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Marie José Kersten, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2120.
https://doi.org/10.1182/blood-2023-174681
Published: 2023
Journal Articles

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

Andre Goy, Caron A. Jacobson, Ian W. Flinn, Brian T. Hill, Wen-Kai Weng, Luke Mountjoy, Oluwole Olalekan, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 106.
https://doi.org/10.1182/blood-2023-174273
Published: 2023
Journal Articles

Real-Word Clinical Management of Patients Treated with Idelalisib in France: A Study of 529 Cases of Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL)

Anne-Sophie Michallet, MD PhD, Emmanuel Gyan, MD PhD, Pierre Feugier, Ana Nunes, PharmD, Tarek Abdelhadi, Loic Ysebaert, MD PhD, Stéphane Leprêtre, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2302.
https://doi.org/10.1182/blood-2018-99-113476
Published: 2018